BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 11326657)

  • 1. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
    Chen ZH; Zhao J; Wu JM; Xiao CG
    Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia].
    Li Y; Xu P; Zhang PA; Su HW; Zhang J
    Zhonghua Nan Ke Xue; 2003 Aug; 9(5):361-3, 366. PubMed ID: 14513646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
    Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
    Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
    Froschermaier SE; Pilarsky CP; Wirth MP
    Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
    Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
    BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.